Abstract:The ubiquitous serine/threonine kinase glycogen synthase kinase 3 beta (Gsk3 beta) differentially regulates macrophage Toll-like receptor (TLR)-triggered pro-and anti-inflammatory cytokine programs. This study was designed to determine the in vivo role and therapeutic potential of Gsk3 beta modulation in tissue inflammation and injury in a murine model of liver partial warm ischemia/reperfusion injury (IRI). As a constitutively activated liver kinase, Gsk3 beta became quickly inactivated (phosphorylated) following IR. The active Gsk3 beta, however, was essential for the development of IRI pathology, as administration of its specific inhibitor, SB216763, ameliorated the hepatocellular damage, evidenced by reduced serum alanine aminotransferase (sALT) levels and well-preserved liver architecture compared with controls. The liver protective effect of Gsk3 beta inhibition was dependent on an immune regulatory mechanism, rather than direct cytoprotection via mitochondria permeability transition pores (MPTP). Indeed: (1) coadministration of SB216763 and atractyloside (MPTP opener) failed to abrogate a local cytoprotective Gsk3 beta inhibition effect; (2) SB216763 selectively inhibited IR-triggered liver pro-inflammatory, but spared interleukin (IL)-10, gene induction programs; and (3) IL-10 neutralization restored liver inflammation and IRI in SB216763-treated mice. Gsk3 beta inactivation by IR was a self-regulatory mechanism in liver homeostasis, critically dependent on phosphoinositide 3 (PI3)-kinase activation, as administration of a PI3 kinase inhibitor, wortmannin, reduced Gsk3 phosphorylation and augmented liver damage. In vitro, IL-10 was critical for the suppression of pro-inflammatory gene programs by Gsk3 inhibition in bone marrow-derived macrophages in response to TLR4 stimulation. Conclusion: Our novel findings document the key immune regulatory function of Gsk3 beta signaling in the pathophysiology of liver IRI, and provide a rationale to target Gsk3 beta as a refined therapeutic strategy to ameliorate liver IRI. (HEPATOLOGY 2011;54:687-696)

Glycogen synthase kinase 3β inhibition promotes human iTreg differentiation and suppressive function

TGF-β–Induced Regulatory T Cells Directly Suppress B Cell Responses Through a Noncytotoxic Mechanism

Cutting Edge: Inhibition of Glycogen Synthase Kinase 3 Activity Induces the Generation and Enhanced Suppressive Function of Human IL-10+ FOXP3+–Induced Regulatory T Cells

Suppressive treg cell activity is potentiated by glycogen synthase kinase 3 β inhibition

Suppressive Regulatory T Cell Activity Is Potentiated By Glycogen Synthase Kinase 3 Beta Inhibition

Inhibition of Glycogen Synthase Kinase 3β Increases the Proportion and Suppressive Function of CD19+CD24hiCD27+ Breg Cells

The Role of STAT3 in Antigen-Igg Inducing Regulatory CD4+Foxp3+T Cells

Glycogen synthase kinase-3 is essential for Treg development and function

Inhibition of Lck/Fyn kinase activity promotes the differentiation of induced Treg cells through AKT/mTOR pathway

Glycogen synthase kinase 3 controls T-cell exhaustion by regulating NFAT activation

Induced regulatory T cells modified by knocking down T-bet in combination with ectopic expression of inhibitory cytokines effectively protect graft-versus-host disease.

Essential Roles Of Tgf-Beta In Anti-Cd3 Antibody Therapy: Reversal Of Diabetes In Nonobese Diabetic Mice Independent Of Foxp3(+) Cd4(+) Regulatory T Cells

Foxp3-expressing CD4+T Cells under the Control of IFN-γ Promoter Prevent Diabetes in NOD Mice

TGF-β–Induced CD4+Foxp3+ T Cells Attenuate Acute Graft-versus-Host Disease by Suppressing Expansion and Killing of Effector CD8+ Cells

GATA3, HDAC6, and BCL6 Regulate FOXP3+ Treg Plasticity and Determine Treg Conversion into Either Novel Antigen-Presenting Cell-Like Treg or Th1-Treg.

Inhibition of Glycogen Synthase Kinase 3 Beta Ameliorates Liver Ischemia Reperfusion Injury by Way of an Interleukin-10-mediated Immune Regulatory Mechanism.

TGF-β-induced CD4+Foxp3+ T Cells Attenuate Acute Graft-Verse-host Disease Via Suppressing Expansion and Killing of Effector CD8+ Cells. (TRAN3P.875)

Blockade of miR-142-3p promotes anti-apoptotic and suppressive function by inducing KDM6A-mediated H3K27me3 demethylation in induced regulatory T cells

Stabilization of Foxp3 by Targeting JAK2 Enhances Efficacy of CD8 Induced Regulatory T Cells in the Prevention of Graft-versus-Host Disease.

Stat5 Polarization Promotes Itregs and Suppresses Human T-Cell Alloresponses While Preserving Ctl Capacity

Therapeutic Potential of TGF-β-induced CD4+ Foxp3+ Regulatory T Cells in Autoimmune Diseases